FDMT (4D Molecular Therapeutics) Interest Coverage: N/A (As of Mar. 2026)


FDMT 4D Molecular Therapeutics Inc FDMT
55 GF Score
Price $11.50
GF Value $214.38
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is 4D Molecular Therapeutics Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. 4D Molecular Therapeutics's Operating Income for the three months ended in Mar. 2026 was $-73.62 Mil. 4D Molecular Therapeutics's Interest Expense for the three months ended in Mar. 2026 was $0.00 Mil. GuruFocus does not calculate 's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. 4D Molecular Therapeutics Inc has enough cash to cover all of its debt. Its financial situation is stable.

The historical rank and industry rank for 4D Molecular Therapeutics's Interest Coverage or its related term are showing as below:


FDMT's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 106.07
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


4D Molecular Therapeutics  (NAS:FDMT) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


4D Molecular Therapeutics Interest Coverage Related Terms


4D Molecular Therapeutics Interest Coverage Historical Data

* Premium members only.

The historical data trend for 4D Molecular Therapeutics's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

4D Molecular Therapeutics Interest Coverage Chart

4D Molecular Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Coverage
Get a 7-Day Free Trial Premium Member Only N/A N/A N/A N/A N/A

4D Molecular Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

FDMT vs KYTX, XOMA, OVID: Interest Coverage Comparison

For the Biotechnology subindustry, 4D Molecular Therapeutics's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


4D Molecular Therapeutics Interest Coverage vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 4D Molecular Therapeutics's Interest Coverage distribution charts can be found below:

* The bar in red indicates where 4D Molecular Therapeutics's Interest Coverage falls into.


FDMT
55GF Score
4D Molecular Therapeutics Inc FDMT
Interest Coverage is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

4D Molecular Therapeutics Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

4D Molecular Therapeutics's Interest Coverage for the fiscal year that ended in Dec. 2025 is calculated as

Here, for the fiscal year that ended in Dec. 2025, 4D Molecular Therapeutics's Interest Expense was $0.00 Mil. Its Operating Income was $-159.55 Mil. And its Long-Term Debt & Capital Lease Obligation was $15.82 Mil.

GuruFocus does not calculate 4D Molecular Therapeutics's interest coverage with the available data.

4D Molecular Therapeutics's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Here, for the three months ended in Mar. 2026, 4D Molecular Therapeutics's Interest Expense was $0.00 Mil. Its Operating Income was $-73.62 Mil. And its Long-Term Debt & Capital Lease Obligation was $15.05 Mil.

GuruFocus does not calculate 4D Molecular Therapeutics's interest coverage with the available data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.

Is 4D Molecular Therapeutics (FDMT) Overvalued in 2026?

Based on GuruFocus' analysis, 4D Molecular Therapeutics stock appears to be undervalued. The current stock price of $11.50 is trading 94.6% below its estimated GF Value™ of $214.38. GuruFocus considers 4D Molecular Therapeutics to be Possible Value Trap.

Key valuation signals for FDMT:

  • Interest Coverage: N/A
  • GF Value™: $214.38 vs. price of $11.50 (94.6% below fair value)
  • GF Score™: 55/100 with 7 warning signs

No single metric tells the full story. See the FDMT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


4D Molecular Therapeutics Business Description

Address 5858 Horton Street, Suite 455, Emeryville, CA, USA, 94608
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
55GF Score

Get the complete analysis for FDMT

Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.50
Price
$214.38
GF Value